Trials / Completed
CompletedNCT03384589
CIRN Pneumococcal Conjugate Vaccine 1 vs. 2 Dose Priming Study
A Randomized Controlled Trial to Compare a 1-dose vs. 2-dose Priming Schedule of 13-valent Pneumococcal Conjugate Vaccine in Canadian Infants; a Canadian Immunization Research Network (CIRN) Study
- Status
- Completed
- Phase
- Phase 2 / Phase 3
- Study type
- Interventional
- Enrollment
- 248 (actual)
- Sponsor
- University of British Columbia · Academic / Other
- Sex
- All
- Age
- 2 Months – 2 Months
- Healthy volunteers
- Accepted
Summary
This study is assessing if a reduced dosing schedule (1+1) of the 13-valent pneumococcal conjugate vaccine (PCV13) is non-inferior to the currently used schedule used in most of Canada.The vaccine is currently usually given as 3 doses at 2, 4 and 12 months of age. This study aims to find out if it is possible to achieve the same protection using just 2 doses, at 2 and 12 months.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | PCV13 | Vaccine against pneumococcal disease |
Timeline
- Start date
- 2018-08-23
- Primary completion
- 2023-03-31
- Completion
- 2023-03-31
- First posted
- 2017-12-27
- Last updated
- 2024-03-04
Locations
1 site across 1 country: Canada
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03384589. Inclusion in this directory is not an endorsement.